Evidence map›Paper›PMID 42885304›Full record

ArticleInternational journal of oncology2026

[Corrigendum] Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER‑inhibitors is accompanied by increased sensitivity to STAT3 inhibition.

Nikolaos Ioannou, Alan M Seddon, Angus Dalgleish, David Mackintosh, Flavio Solca, Helmout Modjtahedi

Abstract readPublished Erratum
In one paragraph

Article in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Nikolaos IoannouSchool of Life Science, Pharmacy and Chemistry, Kingston University London, Kingston-upon-Thames, Surrey KT1 2EE, UK.
Alan M SeddonSchool of Life Science, Pharmacy and Chemistry, Kingston University London, Kingston-upon-Thames, Surrey KT1 2EE, UK.
Angus DalgleishDepartment of Cellular and Molecular Medicine, St George's University of London, London SW17 0RE, UK.
David MackintoshSchool of Life Science, Pharmacy and Chemistry, Kingston University London, Kingston-upon-Thames, Surrey KT1 2EE, UK.
Flavio SolcaBoehringer Ingelheim RCv GmbH & Co KG, 1120 Vienna, Austria.
Helmout ModjtahediSchool of Life Science, Pharmacy and Chemistry, Kingston University London, Kingston-upon-Thames, Surrey KT1 2EE, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the publication of the above article, an interested reader drew the authors' attention to the fact that, for the western blots shown in Fig. 5 on p. 914, the β‑actin blots shown in the rightmost lanes for the 'BcPc3 OSIR' blots (the 'Crixotinib' and 'Af+Cr' lanes of the gel) were strikingly similar to the β‑actin blots shown in Fig. 2B (for the 'BxPc3 parental' blots), albeit with horizontal and vertical resizing of the bands concerned. Upon contacting the authors, they realized that Fig. 5 had inadvertently been assembled incorrectly (the same β‑actin cropped image was used for both samples in question after the files had erroneously being saved under the same name). The authors were able to consult their original data, and provided the Editorial Office with access to the images of the relevant full‑length original blots. The revised version of Fig. 5, now showing the correct data for the β‑actin blots for the 'BcPc3 OSIR' experiments, is shown on the next page. Note that this error did not affect the overall conclusions reported in the study. The authors are grateful to the Editor of

Indexed as

afatinibcancer stem cellsdrug resistanceEMT markersepidermal growth factor receptorerlotinibgemcitabinepancreatic cancer

Identifiers

PMID42885304
PMCPMC13681071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.